| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Annamaria Colao | Q64495559 |
| P2093 | author name string | Cristina de Angelis | |
| Rosario Pivonello | |||
| Marco Mazzella | |||
| Enrico Riccio | |||
| Francesco Garifalos | |||
| Davide Menafra | |||
| P2860 | cites work | Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men | Q70932241 |
| Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism | Q71857797 | ||
| Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens | Q72428866 | ||
| Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study | Q73555560 | ||
| Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism | Q74146698 | ||
| The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity | Q77794785 | ||
| Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age | Q78114999 | ||
| Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome | Q83075501 | ||
| Contrasting testosterone concentrations in type 1 and type 2 diabetes | Q83213999 | ||
| Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity | Q88611374 | ||
| The Metabolic Syndrome in Central Hypogonadotrophic Hypogonadism | Q89079066 | ||
| Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity | Q89287791 | ||
| Cross-sectional and longitudinal determinants of serum sex hormone binding globulin (SHBG) in a cohort of community-dwelling men | Q89567406 | ||
| Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men | Q26770877 | ||
| Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials | Q26822761 | ||
| Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis | Q26827641 | ||
| Male hypogonadism | Q28300144 | ||
| Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies | Q30836337 | ||
| Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis | Q33222142 | ||
| Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels | Q34227587 | ||
| Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis | Q34502187 | ||
| Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes | Q34567831 | ||
| Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? | Q34987666 | ||
| Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer | Q35022837 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis | Q35202889 | ||
| Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes | Q36392574 | ||
| Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. | Q36845500 | ||
| Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups | Q36938377 | ||
| How to recognize late-onset hypogonadism in men with sexual dysfunction | Q37074425 | ||
| Treatment-related diabetes and cardiovascular disease in prostate cancer survivors | Q37268562 | ||
| Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations | Q37310024 | ||
| The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism | Q38057355 | ||
| Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes | Q38140329 | ||
| Testosterone and obesity | Q38485746 | ||
| Late-Onset Hypogonadism | Q56625177 | ||
| Effects of liraglutide on obesity-associated functional hypogonadism in men | Q64230399 | ||
| The effects of testosterone treatment on body composition and metabolism in middle-aged obese men | Q67868889 | ||
| Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues | Q67874681 | ||
| Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. | Q49115376 | ||
| Long-Term Testosterone Administration on Insulin Sensitivity in Older Men with Low or Low-Normal Testosterone Levels. | Q49650593 | ||
| Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. | Q50020065 | ||
| The safety of available treatments of male hypogonadism in organic and functional hypogonadism. | Q50046284 | ||
| Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). | Q50203394 | ||
| Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. | Q50974222 | ||
| Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. | Q51464753 | ||
| The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? | Q51490671 | ||
| Testosterone concentrations in women and men with NIDDM. | Q51595541 | ||
| Insulin resistance, body fat distribution, and sex hormones in men. | Q51596749 | ||
| Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. | Q51602477 | ||
| Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study | Q51606964 | ||
| The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. | Q51621168 | ||
| Effects of testosterone replacement in hypogonadal men. | Q52970270 | ||
| Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. | Q54206191 | ||
| Novel insights in SHBG regulation and clinical implications | Q38516355 | ||
| Obesity and late-onset hypogonadism. | Q38542906 | ||
| Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy | Q38924023 | ||
| A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management | Q39208990 | ||
| Low serum testosterone and sex-hormone-binding-globulin in massively obese men. | Q40838899 | ||
| Pituitary-testicular axis in diabetic men with and without sexual impotence | Q40978304 | ||
| Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS. | Q41722730 | ||
| Changes in body composition during androgen deprivation therapy for prostate cancer | Q42166232 | ||
| Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels | Q42478739 | ||
| The in vitro role of tumour necrosis factor-alpha and interleukin-6 in the hypothalamic-pituitary gonadal axis | Q42500087 | ||
| Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism | Q42537664 | ||
| Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome | Q42861908 | ||
| Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study | Q42934081 | ||
| Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania | Q43053859 | ||
| Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. | Q43705618 | ||
| The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer | Q43732433 | ||
| Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial | Q43809020 | ||
| Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study | Q43843236 | ||
| Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. | Q44185330 | ||
| Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity | Q44210279 | ||
| Steroids in adult men with type 1 diabetes: a tendency to hypogonadism | Q44453217 | ||
| Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity | Q44503829 | ||
| Sex hormones, inflammation and the metabolic syndrome: a population-based study | Q44670623 | ||
| Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. | Q44685104 | ||
| Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. | Q44757133 | ||
| Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. | Q44816778 | ||
| Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. | Q44865591 | ||
| Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control | Q44887127 | ||
| Effect of metformin therapy and dietary supplements on semen parameters in hyperinsulinaemic males | Q45027497 | ||
| Effects of androgen therapy on adipose tissue and metabolism in older men. | Q45096562 | ||
| Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes | Q45142808 | ||
| The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study | Q45145832 | ||
| Type 2 diabetes mellitus and testosterone: a meta-analysis study. | Q45921938 | ||
| Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. | Q45939568 | ||
| Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels | Q46044950 | ||
| Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study. | Q46080336 | ||
| Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes | Q46553591 | ||
| Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. | Q46570705 | ||
| Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. | Q46595277 | ||
| Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect? | Q46679405 | ||
| An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome | Q46689294 | ||
| Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus | Q46697106 | ||
| Low testosterone levels are common and associated with insulin resistance in men with diabetes. | Q46719146 | ||
| Insulin sensitivity during combined androgen blockade for prostate cancer | Q46909972 | ||
| Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. | Q46947824 | ||
| A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate | Q46966328 | ||
| Role of brain insulin receptor in control of body weight and reproduction | Q47229086 | ||
| Alternatives to Testosterone Therapy: A Review. | Q47659892 | ||
| Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats | Q48205089 | ||
| Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism | Q48935307 | ||
| Pathogenesis of the decreased androgen levels in obese men. | Q49109194 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | hypogonadism | Q938107 |
| hypogonadotropic hypogonadism | Q30990102 | ||
| P304 | page(s) | 345 | |
| P577 | publication date | 2019-07-25 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | Metabolic Disorders and Male Hypogonadotropic Hypogonadism | |
| P478 | volume | 10 |
Search more.